Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 2/20 | 0.46 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CCR8 | P51685 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4445805 | 0.88 | TP53 (0.47) | ALDH1A1FABP4NSD2EDNRAMEN1 | |
| SCHEMBL4453000 | 0.87 | NSD2 (0.53) | ALDH1A1FABP4NSD2EDNRAUSP30 | |
| SCHEMBL4453211 | 0.84 | NSD2 (0.52) | ALDH1A1FABP4NSD2SMN1; SMN2CCR8 | |
| SCHEMBL4444987 | 0.84 | NSD2 (0.66) | ALDH1A1FABP4NSD2EDNRAUSP30 | |
| SCHEMBL4444970 | 0.83 | FABP4 (0.56) | ALDH1A1FABP4NSD2EDNRASMN1; SMN2 | |
| SCHEMBL4444610 | 0.83 | FABP4 (0.51) | ALDH1A1FABP4NSD2EDNRACCR8 | |
| SCHEMBL4452477 | 0.83 | MEN1 (0.48) | FABP4EDNRAMEN1KMT2A | |
| SCHEMBL4443167 | 0.82 | NSD2 (0.55) | ALDH1A1FABP4NSD2EDNRAUSP30 | |
| SCHEMBL4623757 | 0.81 | FABP4 (0.52) | ALDH1A1FABP4NSD2EDNRAKMT2A | |
| SCHEMBL4453285 | 0.81 | NSD2 (0.69) | ALDH1A1FABP4NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547716-B2 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2009-06-16 | — | — | US | disclosed |
| EP-1402890-B1 | SULFONAMIDE DERIVATIVES | INST MED MOLECULAR DESIGN INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| US-20040234622-A1 | Sulfonamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-1402890-A1 | SULFONAMIDE DERIVATIVES | Institute of Medicinal Molecular Design, Inc. (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040234622-A1 | Sulfonamide derivatives | PCNA, TOP2A, DDB1 | ALDH1A1 980/4885FABP4 1925/4885NSD2 122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.